Citadel Securities Starts Optimer Pharmaceuticals (OPTR) at Neutral; Expect Difficult Dificid Launch
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
Citadel Securities initiates coverage on Optimer Pharmaceuticals (NASDAQ: OPTR) with a Neutral. PT $10.00.
Citadel analyst says, "Although we view Dificid as a best-in-class treatment for Clostridium difficile (C. diff) associated infection, we believe competition from less expensive, more established treatment options metronidazole and Vancocin could limit Dificid’s peak sales potential. Importantly, we believe cost-sensitive hospital formularies will push Dificid use to only the most severe patients, or those who have failed prior treatments. We currently model peak sales for Dificid of $214.7MM in 2016 based on an estimated peak share of Dificid approaching 12% in the C. diff treatment market."
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $8.59 yesterday.
Citadel analyst says, "Although we view Dificid as a best-in-class treatment for Clostridium difficile (C. diff) associated infection, we believe competition from less expensive, more established treatment options metronidazole and Vancocin could limit Dificid’s peak sales potential. Importantly, we believe cost-sensitive hospital formularies will push Dificid use to only the most severe patients, or those who have failed prior treatments. We currently model peak sales for Dificid of $214.7MM in 2016 based on an estimated peak share of Dificid approaching 12% in the C. diff treatment market."
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $8.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Capital Starts Hut 8 Mining Corp. (HUT) at Buy
- Canaccord Starts Sinda Ltd (SIND) at Spec. Buy
- BMO Capital Starts Prime Medicine (PRME) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
